Clinical trials: Breast Cancer in Situ
brca1 Mutation Carrier, brca2 Mutation Carrier
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
RATIONALE: Cholecalciferol may prevent breast cancer in premenopausal women. PURPOSE: This randomized phase II trial is studying how well cholecalciferol works in preventing breast cancer in premenopausal women.
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
- Trial name
- NCT01097278
- Testing
- cholecalciferol
- Where
- 360 sites in United States
- Volunteers
- 208 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer, DCIS
CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)
This study will prospectively evaluate the technical feasibility, acute toxicity, late effects and oncologic outcomes of CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI) in early stage breast cancer.
- Conditions
- Breast Cancer, DCIS, Invasive Ductal Carcinoma
- Trial name
- CK-SAPBI (NCT02365714)
- Testing
- CK Stereotactic Accelerated Partial Breast Irradiation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Georgetown University
Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
RATIONALE: Zoledronic acid may prevent bone loss and help prevent or lessen musculoskeletal symptoms in women receiving hormone therapy for breast cancer.
- Conditions
- Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer
- Trial name
- NCT01194440
- Testing
- letrozole, zoledronic acid
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial
This phase II trial tests how well fezolinetant works in improving vasomotor symptoms (VMS) in breast cancer patients taking endocrine therapy (ET).
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ
- Trial name
- VEnT (NCT06617455)
- Testing
- Biospecimen Collection, Fezolinetant, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Michigan Rogel Cancer Center
Breast Cancer Screening, Breast Carcinoma in Situ
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BReast CAncer gene (BRCA) carriers) are recommended to have…
- Conditions
- Breast Cancer Screening, Breast Carcinoma in Situ, Breast Cancer
- Trial name
- WISDOM (NCT02620852)
- Testing
- Complete a health questionnaire, Provide a saliva sample for genetic testing, Screening advice based on a comprehensive risk assessment
- Where
- 11 sites in United States
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Ductal Breast Carcinoma In Situ, HER2/Neu Positive
Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ
This randomized phase I/II trial studies the side effects and best dose of lapatinib ditosylate and to see how well it works in treating patients with ductal breast carcinoma in situ.
- Trial name
- NCT00555152
- Testing
- Laboratory Biomarker Analysis, Lapatinib Ditosylate
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
DCIS, LCIS
Molecular Analysis of the Sloane Project
The Sloane Project is a UK wide prospective audit of screen detected non-invasive and atypical breast hyperplasias named after John Sloane an eminent pathologist interested in the field.
- Conditions
- DCIS, LCIS, Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia
- Trial name
- NCT05868252
- Where
- United Kingdom
- Volunteers
- 1,500 people
- Sponsor
- King's College London
DCIS
Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
Breast cancer is one of the most common cancers seriously afflicting women in the United States. Of the one million incident cases that are reported annually there are approximately 193,000 new cases of breast cancer (Greenlee…
- Trial name
- NCT00256217
- Testing
- Anastrozole
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Rita Sanghvi, Mehta
Breast Cancer, Precancerous Condition
Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia
RATIONALE: Polyunsaturated fatty acids are important for normal growth and development. One type, called omega-3 fatty acids (found in fish, fish oil, and some other foods), may affect the growth of abnormal breast cells.
- Trial name
- NCT00627276
- Testing
- omega-3 fatty acid
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Neoplasms, Breast Diseases
Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)
Standard breast MRI studies often have lengthy protocols that make them inherently expensive and time-consuming. Several studies of the use of abbreviated MRI protocols have shown that the shorter protocols have diagnostic…
- Conditions
- Breast Neoplasms, Breast Diseases, Breast Fibroadenoma, Breast Cancer
- Trial name
- NCT04341129
- Testing
- Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Breast Atypical Ductal Hyperplasia, Breast Ductal Carcinoma In Situ
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
This phase III trial studies how well metformin hydrochloride works compared to placebo in preventing breast cancer in patients with atypical hyperplasia or in situ breast cancer.
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Trial name
- NCT01905046
- Testing
- metformin hydrochloride
- Where
- 27 sites in United States
- Volunteers
- 86 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer - Ductal Carcinoma in Situ (DCIS), Breast-Conserving Surgery
Reoperation Rate in Breast-Conserving Surgery Using Confocal Histolog® Scanner for Intraoperative Margin Assessment
This PMPF study is proposed to evaluate in real life the reoperation rates (ROR) of breast cancer and/or DCIS surgery when including the use of the HLS in the context of breast lumpectomy margin assessment.
- Trial name
- SHIELD (NCT05946759)
- Testing
- Histolog Scanner
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- SamanTree Medical SA
Atypical Ductal Hyperplasia
Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia
This research study is studying whether contrast enhanced mammography can predict if atypical ductal hyperplasia will progress to cancer. The device involved in this study is: -Contrast enhanced mammography
- Trial name
- NCT03505372
- Testing
- Contrast enhanced mammography
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Cervical Cancer
EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma
RATIONALE: EF5 may detect the presence of oxygen in tumor cells and help plan effective cancer treatment. PURPOSE: Phase I trial to study the effectiveness of EF5 in detecting the presence of oxygen in tumor cells of patients who…
- Conditions
- Breast Cancer, Cervical Cancer, Head and Neck Cancer, Prostate Cancer
- Trial name
- NCT00004261
- Testing
- EF5, flow cytometry, fluorescent antibody technique
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Ductal Carcinoma In-situ
Diagnostic Study of Early Breast Cancer Using Ultrasound
This is a pilot study designed to investigate new techniques to guide the appropriate diagnosis and treatment of Ductal Carcinoma In-situ (DCIS).
- Trial name
- NCT01391039
- Testing
- Perflutren lipid microsphere
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Sunnybrook Health Sciences Centre
Mastectomy, Breast Neoplasm Malignant Primary
Preoperative vs. Pathologic Size in Breast Cancer: A Prospective Study
Breast cancer, the most prevalent malignancy among women globally, is increasing in incidence. While non-metastatic breast cancer requires surgery, determining the optimal extent of resection remains challenging.
- Trial name
- NCT06505577
- Testing
- No additional intervention
- Where
- South Korea
- Volunteers
- 600 people
- Sponsor
- Incheon St.Mary's Hospital
Ductal Carcinoma in Situ
A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ
The purpose of this study is to find molecular signs (biomarkers) to better understand the role of green tea as an anti-cancer and anti-inflammation agent in women with newly-diagnosed ductal carcinoma in situ (DCIS).
- Trial name
- NCT01060345
- Testing
- Polyphenon E
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
This randomized phase III clinical trial studies how well tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy work in treating patients with breast cancer that has spread from where it began in…
- Conditions
- Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma
- Trial name
- NCT01272037
- Testing
- Anastrozole, Exemestane, Laboratory Biomarker Analysis
- Where
- 1,568 sites in United States, Canada and 8 more
- Volunteers
- 5,018 people
- Sponsor
- National Cancer Institute (NCI)
Cancer Survivor, Early-Stage Breast Carcinoma
Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)
This randomized phase III trial studies how well mindfulness meditation or survivorship education work in improving behavioral symptoms in younger stage 0-III breast cancer survivors.
- Conditions
- Cancer Survivor, Early-Stage Breast Carcinoma, Stage 0 Breast Cancer, Stage IA Breast Cancer
- Trial name
- PTW (NCT03025139)
- Testing
- Educational Intervention, Laboratory Biomarker Analysis, Meditation Therapy
- Where
- 3 sites in United States
- Volunteers
- 96 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Carcinoma, Intraductal, Noninfiltrating, DCIS
Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)
The purpose of this study is to test the hypothesis that chloroquine will reduce the ability of ductal carcinoma in situ (DCIS) to survive and spread.
- Conditions
- Carcinoma, Intraductal, Noninfiltrating, DCIS, Ductal Carcinoma In Situ
- Trial name
- NCT01023477
- Testing
- Chloroquine Standard Dose (500mg/week), Chloroquine Low Dose (250mg/week), Breast Biopsy
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Inova Health Care Services